Gts Securities LLC Aurinia Pharmaceuticals Inc. Call Options Transaction History

Gts Securities LLC

5 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 13, 2024	SELL	$5.32 - $7.33 $116,508 - $160,527	-21,900 Reduced 28.44%	55,100 $403,000
Q2 2024 Aug 14, 2024	BUY	$4.81 - $5.78 $101,971 - $122,536	21,200 Added 37.99%	77,000 $439,000
Q1 2024 May 15, 2024	SELL	$4.93 - $9.31 $697,595 - $1.32 Million	-141,500 Reduced 71.72%	55,800 $279,000
Q4 2023 Feb 14, 2024	SELL	$7.13 - $9.49 $10,695 - $14,235	-1,500 Reduced 0.75%	197,300 $1.77 Million
Q3 2023 Nov 15, 2023	BUY	$7.77 - $12.27 $1.54 Million - $2.44 Million	198,800 New	198,800 $1.54 Million

209

58.7M

1.14M

1.51M

Ticker AUPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 141,892,000
Market Cap $1.15B
Description
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license...

Get notified when there are updates to the investment portfolio of Gts Securities LLC, based on Form 13F filings with the SEC.

Stay updated on Gts Securities LLC with notifications on news.